Novartis wins FDA approval for malaria drug
According to Novartis, Coartem is a fixed-dose combination of two novel antimalarials. It is a highly-effective three-day malaria treatment with cure rates of over 96% even in areas
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.
This Phase IIa randomized, double-blind, placebo-controlled study will evaluate the antiviral activity, safety and pharmacokinetics of TAK-652 by enrolling 40 therapy-experienced, CCR5-naive HIV-1-infected patients into one of four